Observational retrospective study of the treatment of Waldenstrom's macroglobulinemia with ibrutinib in routine clinical practice in Spain.

ABSTRACT:

Background

Waldenström's macroglobulinemia (WM) is a B-cell neoplasia characterized by the infiltration of lymphoplasmacytic lymphoma cells in the bone marrow and abnormal secretion of IgM paraprotein. Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), showed high efficacy in WM clinical trials. However, there is limited real-world data regarding its effectiveness and safety in routine clinical practice.

Objectives

The MACRO study aimed to investigate the clinical, genetic, and demographic characteristics of WM patients treated with ibrutinib-based therapies in Spain. Key secondary objectives included describing effectiveness and safety profile.

Design

Retrospective observational.

Methods

This multicenter, observational, retrospective study included adult pa

SUBMITTER: Fernandez de Larrea C 

PROVIDER: S-EPMC12501444 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature